FFR-guided #PCI using zotarolimus DES provides significantly better long-term value than CABG for treatment of patients with multivessel CAD, with equivalent clinical outcomes at substantially lower cost. https://bit.ly/47vJgJS

#TCT2025 #JACC #cvCABG #cvCAD #CardioSky

In this exploratory randomized trial extension, no statistically significant difference in all-cause mortality was detected between #PCI and CABG. The broad 95% CI does not exclude a clinically meaningful advantage of either strategy. https://bit.ly/4y7OMgr

#ESCCongress #JACC #cvCABG #CardioSky

2️⃣ studies presented at #ESCCongress & published in #JACC offer new insights into the costs & long-term outcomes of CV therapies, w/ one analysis examining mAFP costs & another assessing 20-year all-cause mortality after #PCI vs. #cvCABG.

Read more: https://bit.ly/4iDuZRh #CardioSky

PROCTOR trial findings from #TCT2025 show #PCI of saphenous vein grafts was associated with better 1-year clinical outcomes than PCI of native vessels in patients with prior #cvCABG presenting with graft failure. Read on: https://bit.ly/4qwEBih #JACC

On the latest episode of #EaglesEyeView, Dr. Eagle reviews ACC's Scientific Statement on inflammation & #CVD, LAAO in patients w/ prior intracranial hemorrhage or ischemic stroke, & the NEWTON-CABG CardioLink-5 trial.

👂Listen now: https://bit.ly/3IYLFU7

#cvCABG #CardioSky #MedSky

In the randomized PROCTOR trial, SVG #PCI was assoc with improved 1-yr clinical outcomes compared with native vessel PCI, primarily driven by lower rates of PCI-related MI & clinically driven target coronary territory #revascularization https://bit.ly/4ogyuxh

#TCT2025 #JACC #cvMI #cvCABG #CardioSky